Irish drugmaker Shire Is offering to buy Baxalta for about $30 billion in stock in a move to solidify its position in rare disease treatments.
Deerfield, Illinois-based Baxalta was spun off of Baxter International in July and focuses on bleeding disorders. Dublin-based Shire makes treatments for a range of conditions including attention deficit hyperactivity disorder, epilepsy and hunter syndrome.
In a statement, Shire urged Baxalta to engage in negotiations. It made the offer to the company on July 10 and said the offer implies a value of $45.23 per share, a 36% premium for Baxalta.
Shares of Baxalta rose more than 20% to $40.10 in premarketing trading. Shire's stock fell nearly 3% to $260.92.
